Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;102(4):115618.
doi: 10.1016/j.diagmicrobio.2021.115618. Epub 2021 Dec 16.

Clinical evaluation of nasopharyngeal, midturbinate nasal and oropharyngeal swabs for the detection of SARS-CoV-2

Affiliations

Clinical evaluation of nasopharyngeal, midturbinate nasal and oropharyngeal swabs for the detection of SARS-CoV-2

Byron M Berenger et al. Diagn Microbiol Infect Dis. 2022 Apr.

Abstract

In the setting of supply chain shortages of nasopharyngeal (NP) swabs, we sought to compare the ability of nasopharyngeal, midturbinate nasal, and oropharyngeal swabs (NPS, MTS, and OPS) to detect SARS-CoV-2. Community and hospitalized participants post-COVID-19 diagnosis were swabbed and tested for SARS-CoV-2 by PCR. Thirty-six participants had all 3 swabs collected. Using detection at any site as the standard, the percent positive agreements were 90% (95% CI 74.4-96.5), 80% (70.3-94.7) and 87% (62.7-90.5) for NPS, MTS, and OPS, respectively. Subsequently, 43 participants had OPS and NPS collected. Thirty-nine were positive with a percent positive agreement of 82.1% (95% CI 67.3-91.0) for OPS and 87.2% (73.3-94.4) for NPS. Combining all 79 patients tested, 67 were positive at either site with a positive agreement was 86.5% (76.4-92.7) for OPS and 91.1% (81.8-95.8) for NPS. OPS are an acceptable alternative to NPS for the detection of SARS-CoV-2 infections.

Keywords: COVID-19; Diagnostic testing; Molecular diagnostic techniques; SARS-CoV-2; Specimen handling; Swab.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors report no conflicts of interest relevant to this article.

Similar articles

Cited by

References

    1. Barocas JA, Komaromy M, Haidar D, Barlam TF, Orr BL, Miller NS. Assessment of oropharyngeal specimens for discontinuation of transmission-based COVID-19 precautions. Open Forum Infect Dis. 2020;7:ofaa382. doi: 10.1093/ofid/ofaa382. - DOI - PMC - PubMed
    1. Berenger BM, Conly JM, Fonseca K, Hu J, Louie T, Schneider AR, et al. Saliva collected in universal transport media is an effective, simple, and high-volume amenable method to detect SARS-CoV-2. Clin Microbiol Infect. 2021;274:656–657. doi: 10.1016/j.cmi.2020.10.035. - DOI - PMC - PubMed
    1. Abbott Rapid Diagnostics Jena GmbH. PanbioTM COVID-19 Ag RapidTest Device (NASAL) package insert. December 2020.
    1. European Centre for Disease Prevention and Control. Diagnostic testing and screening for SARS-CoV-2. https://www.ecdc.europa.eu/en/covid-19/latest-evidence/diagnostic-testing. September 8; 2021.
    1. Centers for Disease Control and Prevention. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. Accessed July 9, 2021. Online: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specim...